Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
netFormulary
Home
Treatment Use
Class
Chapters
News
Reports
Contact
SEARCH
Searching for :
Abatacept
Open monograph to display formulary status.
Formulary items found
Status
Description
Section
RED
Abatacept Orencia
®
Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local
BNF
Section
Abatacept
Abatacept
Musculoskeletal System, Arthritis, Immunosuppressants T-Cell Activation Inhibitors
Links found
NICE TA 715 Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375:Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis